Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. (OABI) delivers cutting-edge therapeutic antibody discovery through proprietary transgenic animal platforms and high-throughput screening technologies. This page provides investors and industry professionals with essential updates on the company's scientific advancements, financial performance, and strategic collaborations.
Access consolidated news about OmniAb's drug discovery milestones, including FDA designations, partnership announcements with pharmaceutical leaders, and technology licensing developments. Our repository tracks critical updates ranging from preclinical breakthroughs to quarterly earnings reports.
Key content includes analyses of OmniRat® platform innovations, progress in antibody therapeutic pipelines, and financial disclosures. Bookmark this page to efficiently monitor how OABI's antibody generation capabilities influence biopharmaceutical development timelines and partner-driven revenue streams.
OmniAb (NASDAQ: OABI) has announced two strategic appointments to its Board of Directors: Philip J. Gotwals, Ph.D., and Steve Crouse, while Director Sarah Boyce steps down after nearly six years of service. These changes increase the board size to seven members.
Dr. Gotwals brings 30 years of biopharmaceutical experience, notably as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research, where his team executed over 50 major strategic transactions. He will serve on the Human Capital Management & Compensation Committee and Science & Technology Committee.
Steve Crouse, currently Senior Vice President and General Manager of Bio-Techne's Analytical Solutions Division, contributes over 20 years of life sciences expertise. He will serve on the Audit Committee and Science & Technology Committee.
OmniAb (NASDAQ: OABI) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after U.S. financial markets close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the quarterly results and provide business updates.
Participants can join via phone using U.S. number (800) 549 8228 or International number (289) 819 1520 with Conference ID 96760. A live webcast with slides will also be available.
OmniAb (NASDAQ: OABI) reported its Q4 and full-year 2024 financial results. Q4 revenue increased to $10.8 million from $4.8 million in Q3 2023, while full-year 2024 revenue decreased to $26.4 million from $34.2 million in 2023. The company reported a Q4 net loss of $13.1 million ($0.12 per share) and a full-year net loss of $62.0 million ($0.61 per share).
As of December 31, 2024, OmniAb had 91 active partners and 363 active programs, including 32 OmniAb-derived programs in clinical development or commercialization. The company signed 10 new license agreements in 2024. For 2025, OmniAb projects revenue between $20-25 million and operating expenses of $90-95 million.
The company launched OmniHub™, a unified interface for partners to access discovery campaign data. Notable partner developments include Immunovant's IMVT-1402 progress, with six IND applications cleared, and various clinical advancements in partner programs including batoclimab, acasunlimab, and sugemalimab.
OmniAb (NASDAQ: OABI) will announce its fourth quarter and full-year 2024 financial results on March 18, 2025, after the U.S. financial markets close. The company will also hold a conference call on the same day at 4:30 p.m. Eastern time to discuss the results.
OmniAb (NASDAQ: OABI) has announced its participation in two major investor conferences in March. The company will attend the TD Cowen 45th Annual Health Care Conference from March 3-5 at the Boston Marriott Copley Place, where management will deliver a corporate overview on March 4th at 2:30 p.m. Eastern time and conduct one-on-one investor meetings.
Additionally, OmniAb will participate in the 2025 Leerink Partners Global Healthcare Conference from March 9-12 at the W Hotel South Beach in Miami, with management scheduled for one-on-one investor meetings on March 12th.
OmniAb (NASDAQ: OABI) presented two key technologies at the 2024 Antibody Engineering & Therapeutics Conference in San Diego. The first presentation showcased the company's workflow for building multispecifics, including CD3 T cell and NK cell engagers, highlighting their naturally optimized human sequence immune repertoires and AI-augmented single B cell workflows. The second presentation introduced OmniHub™, a high-dimensional unified bioinformatics portal designed to enhance partner experience through scalable data transfer, advanced visualization, and comprehensive tool access.
The company demonstrated how they discovered developable anti-NKp46 binders with broad epitope coverage, utilizing high-throughput phenotypic screening enhanced with AI-guided next-generation sequencing workflow to identify high-quality leads without extensive ex vivo engineering.
OmniAb (NASDAQ: OABI) reported its Q3 2024 financial results, with revenue dropping to $4.2M from $5.5M in Q3 2023, primarily due to timing of milestones and lower ion channel service revenue. R&D expenses decreased to $13.3M from $13.9M, and G&A expenses fell to $7.1M from $8.5M. Net loss stood at $16.4M, or $0.16 per share, compared to a net loss of $15.7M, or $0.16 per share, in Q3 2023. For the nine months ending September 30, 2024, revenue was $15.6M, down from $29.3M, attributed to a prior $10M milestone. Net loss for this period was $49M, or $0.48 per share, compared to $36.6M, or $0.37 per share, in 2023. OmniAb had $59.4M in cash and short-term investments as of September 30, 2024. The company entered new platform license agreements and expanded partnerships, with 86 active partners and 352 active programs. OmniAb anticipates ending 2024 with a cash balance of $50M-$60M.
OmniAb (NASDAQ: OABI) announced its participation in two major investor conferences in November. The company will attend the Stifel 2024 Healthcare Conference at the Lotte New York Palace Hotel on November 18-19, where CFO Kurt Gustafson will conduct one-on-one investor meetings. Additionally, CEO Matt Foehr will participate in the Jefferies London Healthcare Conference at the Waldorf Hilton from November 19-21, engaging in one-on-one and small-group investor meetings.
OmniAb, Inc. (NASDAQ: OABI) has announced that it will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024. The company will release the results after the close of U.S. financial markets and will host a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on the same day.
Interested parties can access the conference call via phone using the following numbers:
- U.S.: (800) 549 8228
- International: (289) 819 1520
- Conference ID: 94399
Additionally, a live webcast of the call, including slides, will be available. A replay of the webcast will also be accessible after the call.
OmniAb (NASDAQ: OABI) has announced its participation in two upcoming investor conferences in September. The company will be present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11 in New York City, where management will deliver a corporate presentation on September 10th at 2:30 p.m. Eastern Time. Additionally, OmniAb will take part in the Craig-Hallum Bioprocessing Virtual Conference on September 19th, featuring a fireside chat.
At both events, OmniAb's management team will engage in one-on-one meetings with investors, providing opportunities for direct interaction and discussions about the company's progress and future plans. These conferences offer valuable platforms for OmniAb to showcase its developments and connect with the investment community.
